Drugs /

panda-vac

Back to Drugs List

Overview

NCI Definition [1]:
A peptide-based, personalized cancer therapeutic vaccine consisting of up to 8 patient-specific tumor peptides, which are immunogenic and unique to the patient's tumor and identified through DNA and RNA sequencing of a patient's tumor cells, combined with the immunostimulant polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), with potential immunomodulating and antineoplastic activities. Upon administration, personalized and adjusted neoantigen peptide vaccine PANDA-VAC stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens. The vaccine may be adjusted after initial therapy according to sequencing data.

Clinical Trials

View Clinical Trials for panda-vac

Panda-vac has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating panda-vac, 1 is phase 1 (1 open).

PD-L1 High Expression (TPS >= 1%) and PD-L1 Low Expression (TPS >= 1%) are the most frequent biomarker inclusion criteria for panda-vac clinical trials.

Head and neck squamous cell carcinoma and squamous cell lung carcinoma are the most common diseases being investigated in panda-vac clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Panda-Vac
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating panda-vac and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
personalized neoantigen peptide vaccine panda-vac, personalized neoantigen peptide-poly-iclc vaccine panda-vac, personalized and adjusted neoantigen peptide vaccine panda-va
NCIT ID [1]:
C173152

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.